Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
J Immunol. 2010 Apr 1;184(7):3582-9. doi: 10.4049/jimmunol.0902844. Epub 2010 Mar 3.
Genetic studies revealed that SHIP1 limits blood cell production and immune regulatory cell numbers in vivo. We postulated that molecular targeting of SHIP1 might enhance blood cell production and increase immunoregulatory capacity. In this study, we report the identification of a chemical inhibitor of SHIP1, 3 alpha-aminocholestane (3AC). Treatment with 3AC significantly expands the myeloid immunoregulatory cell compartment and impairs the ability of peripheral lymphoid tissues to prime allogeneic T cell responses. In addition, 3AC treatment profoundly increases granulocyte production without triggering the myeloid-associated lung consolidation observed in SHIP1(-/-) mice. Moreover, 3AC also enhances RBC, neutrophil, and platelet recovery in myelosuppressed hosts. Intriguingly, we also find that chemical inhibition of SHIP1 triggers apoptosis of blood cancer cells. Thus, SHIP1 inhibitors represent a novel class of small molecules that have the potential to enhance allogeneic transplantation, boost blood cell production, and improve the treatment of hematologic malignancies.
遗传研究表明,SHIP1 限制了体内血细胞的生成和免疫调节细胞的数量。我们推测,SHIP1 的分子靶向治疗可能会增强血细胞的生成并增加免疫调节能力。在这项研究中,我们报告了一种 SHIP1 的化学抑制剂 3α-氨基胆甾烷(3AC)的鉴定。用 3AC 处理可显著扩大髓系免疫调节细胞区室,并损害外周淋巴组织诱导同种异体 T 细胞反应的能力。此外,3AC 处理还可显著增加粒细胞的生成,而不会引发 SHIP1(-/-)小鼠中观察到的与髓样相关的肺部实变。此外,3AC 还可增强骨髓抑制宿主中 RBC、中性粒细胞和血小板的恢复。有趣的是,我们还发现化学抑制 SHIP1 会触发血癌细胞的凋亡。因此,SHIP1 抑制剂代表了一类新的小分子,有可能增强同种异体移植、促进血细胞生成,并改善血液恶性肿瘤的治疗。